- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Upstream Bio stock jumps 8% on Phase 2 severe asthma data | 1 | Seeking Alpha | ||
| 08.09. | Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 | 141 | GlobeNewswire (Europe) | - Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma - - Verekitug also delivered clinically meaningful improvements in lung function (FEV1)... ► Artikel lesen | |
| 01.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Upstream Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.06. | Upstream Bio präsentiert positive Phase-2-Studiendaten für Verekitug | 2 | Investing.com Deutsch | ||
| 14.06. | Upstream Bio presents positive Phase 2 trial data for verekitug | 2 | Investing.com | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 14.06. | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 | 2 | GlobeNewswire (USA) | ||
| 12.06. | JPMorgan stuft Upstream Bio wegen Umsetzungsrisiken herab | 5 | Investing.com Deutsch | ||
| 12.06. | JPMorgan downgrades Upstream Bio stock rating on execution risks | 1 | Investing.com | ||
| 10.06. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 | 232 | GlobeNewswire (Europe) | WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 03.06. | H.C. Wainwright startet Coverage für Upstream Bio mit "Buy" und hohem Kursziel | 4 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright initiates Upstream Bio stock coverage with buy rating | 1 | Investing.com | ||
| 14.05. | Mizuho lowers Upstream Bio stock price target on operating spend tweaks | 1 | Investing.com | ||
| 14.05. | Mizuho senkt Kursziel für Upstream Bio wegen angepasster Betriebsausgaben | 1 | Investing.com Deutsch | ||
| 13.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Upstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vor | 2 | Investing.com Deutsch |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,869 | +1,24 % | RALLYE bei Valneva: +37,7% Potenzial - Jetzt einsteigen? | ||
| PALATIN TECHNOLOGIES | 10,350 | -5,05 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,911 | -1,83 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,480 | -0,34 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,201 | +1,05 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,554 | -2,57 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,750 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 6,650 | +2,88 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,062 | +0,59 % | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | ||
| ROCKET PHARMACEUTICALS | 2,880 | -2,04 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| VOYAGER THERAPEUTICS | 2,670 | +0,23 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,685 | +5,64 % | Palisade Bio, Inc.: Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum | ||
| PERSONALIS | 14,150 | -1,01 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| XBIOTECH | 1,870 | 0,00 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,56 % bei einem Aktienkurs von 5,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.